Hints and tips:
Related Special Reports
...The advisory board on the beta stage are law firm Orrick, Google, medical device company Zimmer Biomet, insurance group Marsh McLennan and media business Hearst....
...Its co-founder and president John Zimmer told Bloomberg that airport rides, which were up threefold compared with a year earlier, coupled with a rise in weekend and evening trips, were positive signs that...
...The supervoting class B shares held by Mr Green and Mr Zimmer would convert to regular shares if their collective class B holdings fall below 20 per cent of their stakes at the time of the IPO....
...And unlike Facebook’s Mark Zuckerberg, the Lyft founders have not handed themselves majority control of the company while holding less than a fifth of the economic risk....
...At a price of $68 per share, Lyft’s two co-founders, Logan Green and John Zimmer, would see the values of their stakes rise to $569m and $393m respectively....
...Alphabet’s holding will be worth $924m....
...Biomet would be likely to trigger antitrust investigations) but also from a strategic viewpoint....
...Zimmer Biomet, which makes artificial joints and dental devices, saw its shares tumble to their lowest point since April after it lowered its 2016 outlook due to supply chain problems that dragged on its...
...Zimmer Biomet Holdings, which makes artificial joints and dental devices, saw its shares tumble to their lowest point since April after it lowered its 2016 outlook due to supply-chain issues that dragged...
...This week CNN reported that Mr Price had purchased stock worth between $1,000 and $15,000 in a medical device group called Zimmer Biomet Holdings in March....
...Zimmer and Biomet will cut costs by merging, he admits, but adds: “Will they grow their top line? I bet it doesn’t work.”...
...“We believe that for Asia, partnering is the smart international expansion strategy,” said John Zimmer, co-founder and president of Lyft....
...This is, in large part, why Zimmer’s decision to buy privately owned rival Biomet, announced on Tuesday, makes such good sense....
...Zimmer Holdings, a US maker of medical devices, has agreed to buy rival Biomet for $13.4bn, including debt, putting the company among the largest in the industry....
...“We see no urgency for Stryker to acquire S&N, with market share opportunities for grabs from pending Zimmer-Biomet merger . . . and a limited number of other buyers,” said Morgan Stanley The broker reckoned...
...Zimmer shareholders will own 84 per cent of the combined company, with Biomet shareholders owning 16 per cent....
...Recent deals among medical device makers include Zimmer/Biomet and Medtronic/Covidien (the latter is also a so-called tax inversion). And so tax-driven healthcare deals have not emerged from a vacuum....
...Continued deal activity lifted shares of several device makers following Zimmer Holdings’ purchase of rival Biomet for $13.4bn....
...The Medtronic deal is the second big takeover in the sector this year after the $13bn acquisition of Biomet by Zimmer in April to create the world’s biggest maker of hip and knee implants....
...Mr Bohuon’s comments come a week after Indiana-based Zimmer, maker of the eponymous walking frame, agreed to buy orthopaedic products group Biomet for $13bn....
...Another US rival Zimmer, the maker of joint replacement technology, acquired Biomet in a blockbuster deal worth $13.4bn....
...With additional reporting by Lindsay Whipp This article has been ammended to correct an error about Zimmer Holdings’ business....
...As well as Pfizer’s abortive $116bn attempt to take over UK rival AstraZeneca, there have been deals between Zimmer and Biomet, and Novartis and GSK....
...On Thursday, a group including KKR, along with Blackstone, the private equity arm of Goldman and TPG announced they had sold Biomet, a deal done in the peak years to Zimmer for $13bn....
...For this reason, we think the most likely path for Stryker to follow is to await the outcome of the Zimmer-Biomet transaction before making any decision on whether to progress.”...
International Edition